protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist
Company profile
Ticker
PTGX
Exchange
Website
CEO
Dinesh V. Patel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Protagonist Inc, Protagonist Therapeutics Inc
SEC CIK
Corporate docs
Subsidiaries
Protagonist Pty Limited ...
IRS number
980505495
PTGX stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
12 Apr 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
27 Feb 24
8-K
Entry into a Material Definitive Agreement
31 Jan 24
8-K
Other Events
16 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2 Nov 23
8-K
Departure of Directors or Certain Officers
30 Oct 23
Latest ownership filings
4
Asif Ali
19 Apr 24
4
DINESH V PH D PATEL
2 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
HAROLD E SELICK
11 Mar 24
4
DINESH V PH D PATEL
1 Mar 24
4
William D. Waddill
1 Mar 24
4
Asif Ali
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 230.75 mm | 230.75 mm | 230.75 mm | 230.75 mm | 230.75 mm | 230.75 mm |
Cash burn (monthly) | 1.62 mm | (no burn) | 12.78 mm | 12.77 mm | 8.87 mm | 9.90 mm |
Cash used (since last report) | 10.98 mm | n/a | 86.65 mm | 86.60 mm | 60.17 mm | 67.17 mm |
Cash remaining | 219.78 mm | n/a | 144.10 mm | 144.15 mm | 170.59 mm | 163.58 mm |
Runway (months of cash) | 135.8 | n/a | 11.3 | 11.3 | 19.2 | 16.5 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 146 |
Opened positions | 17 |
Closed positions | 43 |
Increased positions | 65 |
Reduced positions | 40 |
13F shares | Current |
---|---|
Total value | 940.56 bn |
Total shares | 68.12 mm |
Total puts | 56.30 k |
Total calls | 528.10 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
BVF | 5.74 mm | $95.82 bn |
Farallon Capital Management | 5.45 mm | $90.85 bn |
RTW Investments | 5.42 mm | $90.33 bn |
BLK Blackrock | 5.23 mm | $87.23 bn |
Biotechnology Value Fund L P | 5.03 mm | $125.65 mm |
Farallon Capital Partners | 4.86 mm | $0.00 |
STT State Street | 3.94 mm | $65.75 bn |
Vanguard | 3.23 mm | $53.85 bn |
JNJ Johnson & Johnson | 2.45 mm | $40.85 bn |
Kynam Capital Management | 1.82 mm | $30.34 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Asif Ali | Common Stock | Sell | Dispose S | No | No | 25.11 | 1,234 | 30.99 k | 37,163 |
1 Apr 24 | Dinesh V PH D Patel | Common Stock | Sell | Dispose S | No | Yes | 28.31 | 25,000 | 707.75 k | 549,590 |
7 Mar 24 | Harold E Selick | Common Stock | Option exercise | Acquire M | No | No | 1.89 | 6,490 | 12.27 k | 27,996 |
7 Mar 24 | Harold E Selick | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.89 | 6,490 | 12.27 k | 0 |
1 Mar 24 | Dinesh V PH D Patel | Common Stock | Sell | Dispose S | No | Yes | 31.62 | 30,000 | 948.60 k | 574,590 |
1 Mar 24 | Waddill William D. | Common Stock | Sell | Dispose S | No | Yes | 31.34 | 12,975 | 406.64 k | 12,000 |
1 Mar 24 | Waddill William D. | Common Stock | Option exercise | Acquire M | No | No | 6.09 | 12,975 | 79.02 k | 24,975 |
1 Mar 24 | Waddill William D. | Stock Option Common Stock | Option exercise | Dispose M | No | No | 6.09 | 12,975 | 79.02 k | 0 |
News
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Maintains $38 Price Target
11 Mar 24
JMP Securities Reiterates Market Outperform on Protagonist Therapeutics, Maintains $42 Price Target
11 Mar 24
Protagonist Therapeutics Announced A Late-breaking Presentation At The American Academy Of Dermatology 2024 Annual Meeting With Results From The Phase 2b FRONTIER 2 Long-term Extension Study Evaluating JNJ-2113 For Moderate-to-severe Plaque Psoriasis
11 Mar 24
JP Morgan Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $37
28 Feb 24
HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $38 Price Target
28 Feb 24
Press releases
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
26 Mar 24
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
11 Mar 24
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
27 Feb 24
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
21 Feb 24
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
7 Feb 24